Sangamo Therapeutics (STU:GBY) Interest Expense : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Sangamo Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sangamo Therapeutics's interest expense for the three months ended in Dec. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sangamo Therapeutics's Operating Income for the three months ended in Dec. 2024 was € -24.82 Mil. Sangamo Therapeutics's Interest Expense for the three months ended in Dec. 2024 was € 0.00 Mil. GuruFocus does not calculate Sangamo Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sangamo Therapeutics Interest Expense Historical Data

The historical data trend for Sangamo Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Interest Expense Chart

Sangamo Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

Sangamo Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sangamo Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Sangamo Therapeutics (STU:GBY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sangamo Therapeutics's Interest Expense for the three months ended in Dec. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was €-24.82 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €25.07 Mil.

Sangamo Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Sangamo Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Sangamo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (STU:GBY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SGMO:USA 0R1D:UK GBY:Germany

Address

501 Canal Boulevard, Richmond, CA, USA, 94804

Website

https://www.sangamo.com

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics Headlines

No Headlines